Clinical Trial: a Phase II Study in Primary Central Nervous System Lymphoma

Study Status: Withdrawn
Recruit Status: Unknown status
Study Type: Interventional

Official Title: High-Dose Methotrexate Plus Steroid Followed by Concurrent Whole Brain Chemoradiation With Temozolomide for Immunocompetent Patients With Primary Central Nervous System Lymphoma<

Brief Summary:

In this study we will test the hypothesis that concurrent chemoradiation (CCRT) with temozolomide after induction chemotherapy by conventional high-dose methotrexate (HD-MTX) plus dexamethasone may be an effective and well tolerated treatment for immunocompetent patients with PCSNL. Corticosteroid can effectively reduce brain edema and corticosteroid alone has resulted in complete or partial remission in about 40% patients with PCNSL. To enhance local disease control, CCRT with temozolomide will be used in the study. Temozolomide is a well-tolerated oral alkylating agent that is able to permeate the BBB. Concurrent temozolomide with WBRT has shown superior effect to WBRT alone for the treatment of metastatic brain tumors and glioblastoma multiforme. In addition, temozolomide has single-agent activity for PCNSL (21% CR in relapsed or refractory PCNSL in a phase II trial).

This is an open-label, non-randomized, multi-center phase II study. The primary end point of is the complete response rate. This study is a two-stage design for testing non-inferiority of the proposed treatment as compared to the approximately 80% response rate reported for conventional treatment. Assuming a non-inferiority margin of 20%, a sample size of 25 subjects, which provides an 80% power for establishment of non-inferiority. At the first stage, 15 subjects are to be enrolled. If equal to or more than 6 patients achieve complete response, the study would accrue additional 10 subjects. The treatment regimen is as follows.

Induction chemotherapy: MS regimen (repeated every 14 days, total 4 cycles)

  • Methotrexate 3.5 g/m2 i.v. infusion 4 hours on day1
  • Methylprednisolone 200 mg/m2/day i.v. infusion 30 minutes, on day1-4 Concurrent chemoradi

    Detailed Summary:

    5 PATIENT SELECTION 5.1 Eligibility Criteria

    Patients must fulfill all the following criteria to be eligible for admission for the study:

    1. Histologically proven central nervous system lymphoma of brain parenchyma with or without leptomeningeal involvement.
    2. No evidence of systemic lymphoma.
    3. Age between 18 years and 75 years.
    4. With at least one measurable lesion, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as 10 mm. See Section 10.2.1 for the evaluation of measurable disease.

    5. Laboratory requirements :

      • Hematology: Neutrophils≧ 1500/mm3, Hemoglobin≧ 10 g/dL, and Platelet count≧ 100000/mm3.
      • Hepatic function: Total bilirubin level≦ 1.5x upper normal limit (UNL), ALT (SGPT) and AST (SGOT)≦ 2.5 x UNL.
      • Renal function: Creatinine≦ 1.5 mg/dL.
    6. No prior malignancy (excluding in situ carcinoma of the cervix or non- melanomatous skin cancer) unless disease free for at least 5 years.
    7. Signed informed consent.
    8. Patients must be accessible for treatment and follow-up. 5.2 Ineligibility Criteria Patient meets any of the following will be excluded form the study.
    1. Patients who are seropositive for HIV, AIDS, use of immunosuppressant or who are post organ transplant are
      Sponsor: National Health Research Institutes, Taiwan

      Current Primary Outcome:

      • Primary : To evaluate objective tumor response rate


      Original Primary Outcome: Same as current

      Current Secondary Outcome:

      • Secondary : To assess toxicity profile
      • To assess time to disease progression


      Original Secondary Outcome: Same as current

      Information By: National Health Research Institutes, Taiwan

      Dates:
      Date Received: April 2, 2007
      Date Started: November 2006
      Date Completion: November 2011
      Last Updated: April 3, 2007
      Last Verified: April 2007